Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.70 |
| ▸ | EGFR | P00533 | 9/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | LCK | P06239 | 9/20 | 0.55 |
| ▸ | SRC | P12931 | 9/20 | 0.55 |
| ▸ | TEK | Q02763 | 9/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967321 | 1.00 | IGF1R (0.70) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2953573 | 0.96 | IGF1R (0.67) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2953577 | 0.96 | IGF1R (0.67) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2959441 | 0.95 | IGF1R (0.71) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2959438 | 0.95 | IGF1R (0.71) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2967078 | 0.94 | IGF1R (0.79) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2967081 | 0.94 | IGF1R (0.79) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2967173 | 0.91 | IGF1R (0.69) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2967170 | 0.91 | IGF1R (0.69) | IGF1REGFRERBB2CYP2D6LCK | |
| SCHEMBL2958149 | 0.90 | IGF1R (0.60) | IGF1REGFRERBB2CYP2D6LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | claimed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | claimed |
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | IGF1R 1941/4885EGFR 591/4885ERBB2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.